

Q2 2018 Performance Positions Sanofi for New Growth Phase

	Q2 2018	Change	Change at CER	H1 2018	Change	Change at CER
IFRS net sales reported	€8,176m	-5.7%	+0.1%	€16,074m	-7.2%	-0.1%
IFRS net income reported	€762m	-26.2%	-	€1,778m	-73.6% ⁽²⁾	-
IFRS EPS reported	€0.61	-25.6%	-	€1.42	-73.4% ⁽²⁾	-
Business net income ⁽¹⁾	€1,558m	-7.9%	+0.4%	€3,156m	-9.4%	+0.4%
Business EPS ⁽¹⁾	€1.25	-6.7%	+1.5%	€2.53	-8.3%	+1.4%

Second-quarter 2018 sales stable⁽³⁾ with strong contributions from Specialty Care and Emerging Markets

- Net sales were €8,176 million, down 5.7% on a reported basis, up 0.1%⁽³⁾ at CER and down 2.5% at CER/CS⁽⁴⁾.
- Sanofi Genzyme sales up 14.1% at CER/CS⁽⁴⁾ (33.1% at CER) driven by Dupixent[®] and consolidation of Bioverativ.
- Vaccines sales down 15.7% reflecting high basis for comparison and expected Pentaxim[®] supply constraint in China.
- CHC sales increased 4.1% supported by growth in Europe and Emerging Markets⁽⁵⁾.
- DCV⁽⁶⁾ GBU sales down 15.6%; global Diabetes franchise sales declined 11.9%, confirming expected trend for year.
- Emerging Markets sales⁽⁵⁾ increased 5.2% with double-digit growth in China.

2018 business EPS guidance range slightly narrowed

- Second-quarter 2018 business EPS⁽¹⁾ up 1.5% at CER to €1.25.
- Second-quarter 2018 IFRS EPS was €0.61 (-25.6%).
- Business EPS⁽¹⁾ in 2018 now expected to grow 3% to 5% at CER⁽⁷⁾ barring unforeseen major adverse events.
- Currency impact on 2018 business EPS is estimated to be around -6% applying the average July exchange rates.

Key achievements in sustaining innovation in R&D

- Sanofi completed the acquisition of Ablynx in May, internalizing the innovative Nanobody[®] platform.
- Positive CHMP recommendation for Cablivi[™] for aTTP⁽⁸⁾.
- Phase 1/2a data on BIVV001, an extended factor VIII therapy, demonstrated half-life of 37 hours.
- A phase 2/3 study is being initiated on venglustat, an oral glucosylceramide synthase (GCS) inhibitor, in ADPKD⁽⁹⁾.
- Positive phase 3 trial evaluating Dupixent[®] to treat moderate-to-severe atopic dermatitis in adolescents.
- Priority review granted in the U.S. to cemiplimab for the treatment of CSCC⁽¹⁰⁾.
- Zynquista[™] (sotagliflozin) accepted for review by the FDA in type 1 diabetes.
- Praluent[®] ODYSSEY OUTCOMES results submitted to the FDA and EMA in Q2.

Sanofi Chief Executive Officer, Olivier Brandicourt, commented:

“In the second quarter, we achieved significant milestones in building our new Rare Blood Disorder franchise and the successful continued execution of the global roll-out of Dupixent[®]. As the impact from the U.S. losses of exclusivity peaked in the second quarter, the growth of our diversified businesses largely compensated for these headwinds. We look forward to entering a new growth phase led by our increasing focus on Specialty Care and our leadership positions in Emerging Markets and Vaccines.”

(1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (see Appendix 8 for definitions). The consolidated income statement for Q2 2018 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) Excluding Animal Health gain on disposal, first-half IFRS net income was down 22.6% and first-half IFRS EPS was down 22.4%; (3) Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 10); (4) Constant Structure: Adjusted for Bioverativ acquisition; (5) See definition page 8; (6) DCV: Diabetes and Cardiovascular; (7) 2017 business EPS was €5.52; (8) Acquired thrombotic thrombocytopenic purpura; (9) Autosomal Dominant Polycystic Kidney Disease; (10) Cutaneous Squamous Cell Carcinoma

2018 Second-quarter and first-half Sanofi sales

Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER⁽¹¹⁾.

In the second quarter of 2018, Company sales were €8,176 million, down 5.7% on a reported basis. Exchange rate movements had a negative effect of 5.8 percentage points mainly driven by the movement of the U.S. Dollar accompanied by the Brazilian Real, Argentine Peso, Turkish Lira, Japanese Yen and Russian Ruble. At CER, Company sales increased 0.1%.

First-half Company sales reached €16,074 million, down 7.2% on a reported basis. Exchange rate movements had an unfavorable effect of 7.1 percentage points. At CER, Company sales were down 0.1%.

Global Business Units

The table below presents sales by Global Business Unit (GBU). Please note that Emerging Markets sales for Specialty Care and Diabetes and Cardiovascular are included in the General Medicines and Emerging Markets GBU.

Net Sales by GBU (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Sanofi Genzyme (Specialty Care) ^(a)	1,808	+33.1%	3,268	+24.8%
Diabetes and Cardiovascular ^(a)	1,107	-15.6%	2,195	-15.6%
General Medicines & Emerging Markets ^(b)	3,335	-3.7%	6,736	-2.6%
Total Pharmaceuticals	6,250	+1.9%	12,199	+0.5%
Consumer Healthcare (CHC)	1,115	+4.1%	2,353	+3.0%
Sanofi Pasteur (Vaccines)	811	-15.7%	1,522	-9.3%
Total net sales	8,176	+0.1%	16,074	-0.1%

(a) Does not include Emerging Markets sales- see definition page 8; (b) Includes Emerging Markets sales for Diabetes & Cardiovascular and Specialty Care

Global Franchises

The tables below present second-quarter and first-half 2018 sales by global franchise, including Emerging Markets sales, to facilitate comparisons. Appendix 1 provides a reconciliation of sales by GBU and franchise.

Net sales by Franchise (€ million)	Q2 2018	Change at CER	Developed Markets	Change at CER	Emerging Markets	Change at CER
Specialty Care	2,071	+29.5%	1,808	+33.1%	263	+10.3%
Diabetes and Cardiovascular	1,511	-9.4%	1,107	-15.6%	404	+12.2%
Established Rx Products	2,266	-7.9%	1,301	-17.3%	965	+7.8%
Consumer Healthcare (CHC)	1,115	+4.1%	723	+0.8%	392	+10.1%
Generics	402	-1.6%	230	-6.8%	172	+5.3%
Vaccines	811	-15.7%	482	-15.9%	329	-15.5%
Total net sales	8,176	+0.1%	5,651	-2.1%	2,525	+5.2%

Net sales by Franchise (€ million)	H1 2018	Change at CER	Developed Markets	Change at CER	Emerging Markets	Change at CER
Specialty Care	3,781	+23.1%	3,268	+24.8%	513	+13.4%
Diabetes and Cardiovascular	2,995	-9.0%	2,195	-15.6%	800	+15.0%
Established Rx Products	4,586	-7.1%	2,628	-16.7%	1,958	+8.7%
Consumer Healthcare (CHC)	2,353	+3.0%	1,552	-1.6%	801	+12.3%
Generics	837	-0.3%	486	-3.7%	351	+4.1%
Vaccines	1,522	-9.3%	953	-4.2%	569	-16.7%
Total net sales	16,074	-0.1%	11,082	-3.1%	4,992	+6.8%

(11) See Appendix 10 for definitions of financial indicators.

Pharmaceuticals

Second-quarter Pharmaceutical sales were up 1.9% to €6,250 million driven by the Rare Blood Disorder and Immunology franchises which were partially offset by Diabetes and Established Rx Products. First-half sales for Pharmaceuticals increased 0.5% to €12,199 million.

Rare Disease franchise

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Myozyme® / Lumizyme®	209	+7.8%	405	+9.4%
Fabrazyme®	188	+6.3%	358	+6.5%
Cerezyme®	181	+2.6%	356	+6.2%
Aldurazyme®	52	-1.8%	103	+1.8%
Cerdelga®	38	+32.3%	74	+29.0%
Others Rare Disease	75	+5.3%	142	-5.5%
Total Rare Disease	743	+6.1%	1,438	+6.5%

In the second quarter, **Rare Disease** sales increased 6.1% to €743 million, driven by Europe (up 6.2% to €256 million), Emerging Markets (up 7.1% to €139 million) and Rest of the World (up 12.0% to €85 million). In the U.S., second-quarter Rare Disease sales grew 3.7% to €263 million. First-half Rare Disease sales increased 6.5% to €1,438 million.

Second-quarter **Gaucher** (Cerezyme® and Cerdelga®) sales were up 6.7% to €219 million, supported by the increasing penetration of Cerdelga® in Europe and the U.S. and the sustained growth of Cerezyme® in Emerging Markets. Second-quarter Cerdelga® sales increased 32.3% to €38 million, with sales doubling in Europe (€12 million). First-half Gaucher sales were €430 million, up 9.5%.

Second-quarter **Myozyme®/Lumizyme®** sales grew 7.8% to €209 million, supported by positive trends in naïve patient accruals. Second-quarter Myozyme®/Lumizyme® sales increased 9.2% to €95 million in Europe and 8.8% to €69 million in the U.S., respectively. First-half Myozyme®/Lumizyme® sales increased 9.4% to €405 million.

Second-quarter **Fabrazyme®** sales grew 6.3% to €188 million. Second-quarter sales in the U.S. and Europe increased 5.2% (to €93 million) and 9.8% (to €45 million), respectively. First-half Fabrazyme® sales were up 6.5% to €358 million.

Multiple Sclerosis franchise

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Aubagio®	404	+1.2%	775	+6.0%
Lemtrada®	102	-12.9%	207	-10.8%
Total Multiple Sclerosis	506	-2.0%	982	+2.0%

Second-quarter **Multiple Sclerosis** (MS) sales decreased 2.0% to €506 million, reflecting lower Lemtrada® sales and a high basis of comparison for Aubagio® in Europe. First-half MS sales increased 2.0% to €982 million.

Second-quarter **Aubagio®** sales increased 1.2% to €404 million, supported by the U.S. performance (up 9.1% to €287 million) which was offset by lower sales in Europe (down 21.1% to €89 million) reflecting the high basis of comparison from clinical trial supply orders of approximately €30 million in the second quarter of 2017. First-half Aubagio® sales increased 6.0% to €775 million.

In the second quarter, **Lemtrada®** sales decreased 12.9% to €102 million due to lower U.S. sales (down 20.6% to €46 million) reflecting increased competition as well as its unique dosing and durable effect. In Europe, Lemtrada® sales were down 2.1% to €45 million. First-half Lemtrada® sales decreased 10.8% to €207 million.

Immunology franchise

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Dupixent®	176	-	283	-
Kevzara®	20	-	30	-
Total Immunology	196	-	313	-

Dupixent® (collaboration with Regeneron) for the treatment of moderate-to-severe atopic dermatitis in adults generated sales of €176 million in the second quarter compared to €26 million in the second quarter of 2017. In the U.S., Dupixent® was launched in April 2017 and reached sales of €151 million in the second quarter. Demand for the product remains strong with more than 50,000 patients having been prescribed to date and total prescriptions (source: IQVIA weekly TRx data) increasing 27% sequentially in the second quarter. Trade inventory at the end of the second quarter is estimated to have been in the middle of the normal range of three to five weeks. Outside the U.S., Dupixent® was launched in Germany in December 2017 and the Netherlands, Canada, Denmark, Sweden and Japan during the first half of 2018. Second-quarter sales in Europe were €16 million. First-half Dupixent® sales were €283 million compared to €26 million in the first half of 2017.

Kevzara® (collaboration with Regeneron) for rheumatoid arthritis was launched in the U.S. in June 2017, in Germany, the UK, the Netherlands during the second half of last year and in Japan, Belgium, Sweden and Finland in the first half of 2018. Second-quarter Kevzara® sales were €20 million, of which €15 million were generated in the U.S. reflecting improved U.S. commercial coverage. First-half Kevzara® sales were €30 million.

Rare Blood Disorder franchise

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Eloctate®	176	-	219	-
Alprolix®	81	-	102	-
Total Rare Blood Disorder	257	-	321	-

Bioverativ was consolidated in Sanofi's Financial Statements from March 9, 2018. Second-quarter sales of the Rare Blood Disorder franchise were €257 million, up 15.5% on a pro forma basis⁽¹²⁾ including non U.S. sales of €38 million with Japan as the primary contributor. Eloctate® and Alprolix® were launched in Colombia in the first quarter of 2018. In the first half of 2018, consolidated sales of the Rare Blood Disorder franchise were €321 million, up 18.3% on a pro forma basis⁽¹²⁾.

Eloctate®, a recombinant antihemophilic Factor VIII, Fc Fusion Protein, indicated for the treatment of hemophilia A, generated sales of €176 million in the second quarter, up 20.0% on a pro forma basis⁽¹²⁾. First-half consolidated Eloctate® sales were €219 million, up 23.3% on a pro forma basis⁽¹²⁾.

Alprolix®, a recombinant coagulation Factor IX, Fc Fusion Protein, indicated for the treatment of hemophilia B, generated sales of €81 million in the second quarter, up 6.6% on a pro forma basis⁽¹²⁾ despite a delay in government contracting in Canada. First-half consolidated Alprolix® sales were €102 million, up 8.9% on a pro forma basis⁽¹²⁾.

Oncology franchise

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Jevtana®	103	+10.0%	202	+10.2%
Thymoglobulin®	74	+3.9%	144	+6.1%
Eloxatin®	46	+4.4%	90	+5.6%
Mozobil®	44	+15.0%	82	+10.0%
Taxotere®	41	0.0%	84	-1.1%
Zaltrap®	24	+38.9%	46	+41.2%
Others	37	-31.7%	79	-44.5%
Total Oncology	369	+2.4%	727	-1.8%

(12) Growth comparing full second-quarter 2018 sales versus full second-quarter 2017 sales, and full first-half 2018 sales versus full first-half 2017 sales at CER. Unaudited data.

Second-quarter **Oncology** sales increased 2.4% to €369 million. Consistent with the Company's portfolio prioritization efforts, Sanofi sold Leukine[®] on January 31, 2018. Excluding Leukine[®], oncology second-quarter sales were up 5.1%. First-half Oncology sales were down 1.8% to €727 million and up 4.3% excluding Leukine[®].

Jevtana[®] sales were up 10.0% to €103 million in the second quarter supported by the performance in the U.S. (up 14.6% to €43 million). First-half Jevtana[®] sales increased 10.2% to €202 million. In the second quarter, **Thymoglobulin[®]** and **Eloxatin[®]** sales increased 3.9% (to €74 million) and 4.4% (to €46 million), respectively, with growth driven by China. First-half sales of Thymoglobulin[®] and Eloxatin[®] increased 6.1% (to €144 million) and 5.6% (to €90 million), respectively.

Diabetes franchise

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Lantus [®]	891	-20.6%	1,802	-19.1%
Toujeo [®]	217	+7.9%	414	+10.7%
Total glargine	1,108	-16.2%	2,216	-14.9%
Apidra [®]	92	+5.4%	183	+3.1%
Amaryl [®]	87	+9.5%	170	+5.8%
Insuman [®]	23	-17.2%	47	-12.5%
Lyxumia [®]	6	-14.3%	11	-14.3%
Soliqua [®]	17	+260.0%	26	+222.2%
Total Diabetes	1,366	-11.9%	2,722	-10.9%

In the second quarter, global **Diabetes** sales decreased 11.9% to €1,366 million, due to lower glargine (Lantus[®] and Toujeo[®]) sales in the U.S. Second-quarter U.S. Diabetes sales were down 30.1% to €525 million, reflecting the previously announced changes in coverage of the Part D business and a continued decline in average U.S. glargine net prices. Second-quarter sales in Emerging Markets increased 11.8% to €401 million. Second-quarter sales in Europe increased 0.3% to €325 million, supported by Toujeo[®] growth. First-half global Diabetes sales decreased 10.9% to €2,722 million.

Second-quarter **glargine** (Lantus[®] and Toujeo[®]) sales decreased 16.2% to €1,108 million. U.S. glargine sales were down 32.2% to €489 million, reflecting the aforementioned changes in coverage in Part D and a continued decline in average U.S. glargine net prices. In Europe, glargine sales increased 0.8% to €249 million due to strong Toujeo[®] performance, despite biosimilar glargine competition in several European markets. First-half glargine sales decreased 14.9% to €2,216 million.

In the second quarter, **Lantus[®]** sales were €891 million, down 20.6%. In the U.S., Lantus[®] sales decreased 33.9% to €403 million mainly reflecting lower average net price and changes in coverage in Part D. In Europe, second-quarter Lantus[®] sales were €174 million, down 9.8% due to biosimilar glargine competition and patients switching to Toujeo[®]. In Emerging Markets, second-quarter Lantus[®] sales were up 1.1% to €244 million. First-half Lantus[®] sales decreased 19.1% to €1,802 million.

Second-quarter **Toujeo[®]** sales were €217 million, up 7.9%. In the U.S., second-quarter Toujeo[®] sales were €86 million, down 23.0%. In Europe and Emerging Markets, second-quarter Toujeo[®] sales were €75 million (up 38.9%) and €37 million (versus €24 million), respectively. First-half Toujeo[®] sales increased 10.7% to €414 million.

Soliqua[®] 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) was launched in the U.S. in January 2017 and **Suliqua[™]** was also launched in several European countries in 2017. Second-quarter and first-half Soliqua[®] 100/33 / Suliqua[™] sales were €17 million and €26 million, respectively.

Amaryl[®] sales were €87 million, up 9.5% in the second quarter, of which €74 million were generated in Emerging Markets (up 11.4%). First-half Amaryl[®] sales were up 5.8% at €170 million,

Second-quarter **Apidra[®]** sales increased 5.4% to €92 million. Lower sales in the U.S. (down 22.2% to €19 million) were offset by strong growth in Emerging Markets (up 29.2% to €27 million). First-half Apidra[®] sales increased 3.1% to €183 million.

Cardiovascular franchise

Second-quarter **Praluent**[®] (collaboration with Regeneron) sales increased 54.8% to €62 million, of which €35 million was generated in the U.S. and €22 million in Europe. First-half Praluent[®] sales increased 55.3% to €111 million. The Company is in active discussions with a number of U.S. payers to simplify utilization management (UM) criteria and improve access for patients in return for greater rebates, consistent with the new commercial policy for Praluent[®] announced in March. As a result of recent payer agreements, around 30% of Commercial lives now benefit from improved UM criteria. Negotiations with U.S. payers are ongoing with additional contract decisions expected to be finalized in the next few months.

Second-quarter and first-half **Multaq**[®] sales were up 7.2% (to €83 million) and down 1.7% (to €162 million), respectively.

Established Rx Products

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Lovenox [®]	377	-2.2%	768	-1.5%
Plavix [®]	374	+0.3%	761	+4.6%
Aprovel [®] /Avapro [®]	171	-6.3%	343	-4.7%
Renvela [®] /Renagel [®]	100	-57.3%	201	-55.7%
Synvisc [®] /Synvisc-One [®]	92	-13.8%	160	-14.6%
Myslee [®] /Ambien [®] /Stilnox [®]	55	-7.8%	116	-8.0%
Allegra [®]	28	-11.8%	80	-14.7%
Other	1,069	-1.5%	2,157	-2.0%
Total Established Rx Products	2,266	-7.9%	4,586	-7.1%

In the second quarter, **Established Rx Products** sales decreased 7.9% to €2,266 million. This reflected generic competition to Renvela[®]/Renagel[®] (sevelamer) in the U.S., which more than offset growth in Emerging Markets (up 7.8% to €965 million). First-half Established Rx Products sales decreased 7.1% to €4,586 million.

Second-quarter **Lovenox**[®] sales decreased 2.2% to €377 million, reflecting increased competition in Europe (down 5.8% to €227 million), which offset the growth in Emerging Markets (up 10.6% to €121 million). Biosimilars are available in the UK, Germany and Italy. First-half Lovenox[®] sales were down 1.5% to €768 million.

In the second quarter, **Plavix**[®] sales were up 0.3% to €374 million reflecting generic competition in Japan (sales down 28.1% to €42 million) offset by strong growth in Emerging Markets (up 7.1% to €278 million) driven by China. First-half Plavix[®] sales increased 4.6% to €761 million.

Second-quarter **Aprovel**[®]/**Avapro**[®] sales decreased 6.3% to €171 million, reflecting the strong performance in China offset by the impact of generic competition in Japan. First-half Aprovel[®]/Avapro[®] sales decreased 4.7% to €343 million.

Second-quarter **Renvela**[®]/**Renagel**[®] (sevelamer) sales decreased 57.3% to €100 million, due to generic competition in the U.S. (down 68.9% to €60 million). First-half Renvela[®]/Renagel[®] sales decreased 55.7% to €201 million.

Generics

In the second quarter, **Generics** sales decreased 1.6% to €402 million. Sales in Emerging Markets sales were up 5.3% (to €172 million) and sales in Europe were down 3.2% (to €183 million). In June, Sanofi and Advent International finished negotiations for the acquisition by Advent of Zentiva, Sanofi's European generics business and the companies signed a Share Purchase Agreement worth €1.9 billion (enterprise value). The transfer of the Zentiva business to Advent is anticipated during the course of the fourth quarter 2018. The transaction remains subject to approval of the regulatory authorities.

Consumer Healthcare

CHC sales by geography and category are provided in Appendix 1.

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Allergy Cough & Cold	239	+2.0%	580	-4.2%
of which Allegra®	99	+1.9%	229	+2.0%
of which Mucosolvan®	22	+53.3%	49	+13.0%
of which Xyzal®	7	-	21	-52.9%
Pain	304	+10.4%	628	+9.6%
of which Doliprane®	77	+6.8%	161	+4.5%
of which Buscopan®	50	+39.0%	104	+42.2%
Digestive	248	+8.6%	496	+11.7%
of which Dulcolax®	56	+3.6%	109	+12.6%
of which Enterogermina®	45	+16.7%	94	+14.6%
of which Essentiale®	46	+8.9%	89	+11.8%
of which Zantac®	31	+10.0%	62	+21.1%
Nutritionals	166	+0.6%	330	+2.0%
Other	158	-6.0%	319	-5.6%
of which Gold Bond®	48	+6.0%	97	+9.0%
Total Consumer Healthcare	1,115	+4.1%	2,353	+3.0%

In the second quarter, **Consumer Healthcare** (CHC) sales increased 4.1% to €1,115 million, led by good growth in Emerging Markets and Europe which more than offset a decline in U.S. sales due the late onset of the allergy season and private label competition. First-half CHC sales increased 3.0% to €2,353 million.

In **Europe**, second-quarter CHC sales were up 6.6% to €324 million driven by Pain (up 8.9%) and Allergy Cough & Cold (up 11.9%) categories. First-half CHC sales in Europe were stable at €706 million.

In **the U.S.**, second-quarter CHC sales decreased 5.8% to €254 million due to the late onset of the allergy season which impacted sales of Allegra®, Nasacort® and Xyzal®. Nasacort® was additionally impacted by private label competition. In the U.S., first-half CHC sales decreased 5.3% to €541 million.

In **Emerging Markets**, second-quarter CHC sales increased 10.1% to €392 million driven by double-digit growth of Allergy, Cough and Cold (up 13.9%), Pain (up 19.1%) and Digestive (up 17.6%) categories primarily in Latin America. In the first half, Emerging Markets CHC sales increased 12.3% to €801 million.

Vaccines

Net sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
Polio/Pertussis/Hib vaccines (incl. Hexaxim® / Hexyon®, Pentacel®, Pentaxim® and Imovax®)	354	-20.3%	734	-12.8%
Travel and other endemic vaccines	126	+15.9%	228	+9.6%
Meningitis/Pneumo vaccines (incl. Menactra®)	116	-36.4%	205	-22.1%
Influenza vaccines (incl. Vaxigrip®, Fluzone HD® & Fluzone®)	98	+7.1%	127	+0.7%
Adult Booster vaccines (incl. Adacel®)	94	-14.8%	186	+2.1%
Other vaccines (including Dengvaxia®)	23	-7.7%	42	-23.3%
Total Vaccines	811	-15.7%	1,522	-9.3%

Second-quarter **Vaccines** performance was impacted as expected by the supply constraint of Pentaxim® in China, a high basis of comparison for Menactra® and phasing for the Polio/Pertussis/Hib franchise. Second-quarter Vaccines sales decreased by 15.7% to €811 million reflecting a decline of 15.5% to €329 million in Emerging Markets and a decrease of 25.4% to €265 million in the U.S. As anticipated, first-half Vaccines sales were lower than in the first half of 2017, down 9.3% to €1,522 million. In the second half of 2018, sales of the Vaccines GBU are expected to grow in mid-single digit, supported by the growth of the Polio/Pertussis/Hib franchise, including the progressive recovery in Pentaxim® supply in China as of the third quarter.

In the second quarter, **Polio/Pertussis/Hib** (PPH) vaccines sales decreased 20.3% to €354 million, reflecting the supply constraint for Pentaxim[®] in China and impacted by the timing of tender business for Pentaxim[®] and Hexaxim[®] in Emerging Markets. In the U.S., PPH vaccines sales decreased 25.0% to €65 million, reflecting inventory fluctuation for Pentacel[®] and Daptacel[®]. First-half Polio/Pertussis/Hib vaccines sales decreased 12.8% to €734 million.

Second-quarter **Travel and other endemic vaccines** sales were €126 million up 15.9% supported by increased demand for Yellow fever and Typhim[®]. First-half Travel and other endemic vaccines sales were up 9.6% to €228 million.

Second-quarter **Menactra[®]** sales decreased 31.5% to €116 million due a high basis for comparison. In the second quarter of the previous year, Menactra[®] sales benefited from CDC order phasing in the U.S. and a meningitis outbreak in Australia which together accounted for €58 million. First-half Menactra[®] sales decreased 16.6% to €205 million.

Second-quarter **Influenza vaccines** sales were up 7.1% to €98 million driven by the Southern Hemisphere flu campaign. First-half Influenza vaccines sales increased 0.7% to €127 million.

Second-quarter **Adult Booster** vaccines sales decreased 14.8% to €94 million due to lower sales in the U.S. (down 21.1% to €56 million) reflecting timing of orders which are expected to be weighted in the second half of 2018. First-half Adult Booster vaccines sales increased 2.1% to €186 million.

Company sales by geographic region

Sanofi sales (€ million)	Q2 2018	Change at CER	H1 2018	Change at CER
United States	2,479	-4.4%	4,677	-6.3%
Emerging Markets^(a)	2,525	+5.2%	4,992	+6.8%
of which Asia	993	+9.0%	1,993	+9.2%
of which Latin America	648	+4.5%	1,298	+8.9%
of which Africa, Middle East	539	-7.4%	1,030	-4.3%
of which Eurasia ^(b)	307	+17.3%	597	+14.3%
Europe^(c)	2,342	+0.1%	4,758	+0.3%
Rest of the World^(d)	830	-0.7%	1,647	-2.1%
of which Japan	430	-3.0%	875	-5.4%
Total Sanofi sales	8,176	+0.1%	16,074	-0.1%

(a) World excluding U.S., Canada, Western & Eastern Europe (except Eurasia), Japan, South Korea, Australia, New Zealand and Puerto Rico

(b) Russia, Ukraine, Georgia, Belarus, Armenia and Turkey

(c) Western Europe + Eastern Europe except Eurasia

(d) Japan, South Korea, Canada, Australia, New Zealand, Puerto Rico

Second-quarter sales in the **U.S.** decreased 4.4% to €2,479 million, reflecting the good performances of Dupixent[®] and Aubagio[®] and consolidation of Elocate[®] and Alprolix[®] sales offset by lower sales in Diabetes (down 30.1%) and Vaccines (down 25.4%) as well as generic competition for sevelamer. In the U.S., first-half sales decreased 6.3% to €4,677 million.

Second-quarter sales in **Emerging Markets** grew 5.2% to €2,525 million, mainly driven by Established Rx Products (up 7.8%), Diabetes (up 11.8%) and CHC (up 10.1%). In Asia, second-quarter sales were up 9.0% to €993 million, reflecting strong performance in China (up 11.0% to €613 million) despite Pentaxim[®] local supply constraint. In Latin America, second-quarter sales increased 4.5% to €648 million. Second-quarter sales in Brazil were up 1.1% to €240 million impacted by lower sales in Rare Disease and Diabetes. In Africa and the Middle East region, second-quarter sales were €539 million down 7.4% (down 5.0% excluding Maphar in Morocco in which Sanofi sold a controlling stake at the end of Q2 2017 and therefore is no longer consolidating sales) reflecting lower Vaccines sales in South Africa and Middle East. Second-quarter sales in the Eurasia region increased 17.3% to €307 million, supported by strong growth in Turkey and Russia. Second-quarter sales in Russia were €168 million up 17.2% driven by Pharma and Vaccines. In Emerging Markets, first-half sales increased 6.8% to €4,992 million.

Second-quarter sales in **Europe** were €2,342 million, up 0.1% mainly driven by Rare Disease (up 6.2%), CHC (up 6.6%) and the roll-out of Dupixent[®] and Praluent[®] which offset lower sales in Established Rx Products (down 3.6%) and Multiple Sclerosis (down 15.5%). In Europe, first-half sales increased 0.3% to €4,758 million.

Sales in **Japan** decreased 3.0% to €430 million in the second quarter, due to lower sales of Plavix[®] and Aprovel[®] generic competition. In Japan, first-half sales decreased 5.4% to €875 million.

R&D update

Consult Appendix 6 for full overview of Sanofi's R&D pipeline

Regulatory update

Regulatory updates since April 27, 2018 include the following:

- In June, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of **Cablivi**TM (caplacizumab) in the European Union for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. CabliviTM was developed by Ablynx, a Sanofi Company.
- In May, **Zynquista**TM (sotagliflozin) was accepted for review by the U.S. Food and Drug Administration (FDA) in type 1 diabetes.
- In April, the FDA accepted for priority review the Biologics License Application (BLA) for **cemiplimab** (collaboration with Regeneron) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.
- The results of the ODYSSEY OUTCOMES study, which showed **Praluent**[®] (collaboration with Regeneron) significantly reduced the risk of major adverse cardiovascular events in patients who had suffered a recent acute coronary syndrome, were submitted to the FDA and EMA in the second quarter.

At the end of April 2018, the R&D pipeline contained 87 projects including 40 new molecular entities in clinical development. 36 projects are in phase 3 or have been submitted to the regulatory authorities for approval.

Portfolio update

Phase 3:

- In June, positive non-inferiority results of the BRIGHT study comparing **Toujeo**[®] to insulin degludec were presented at the American Diabetes Association (ADA).
- In May, Sanofi and Regeneron announced that a pivotal phase 3 trial evaluating **Dupixent**[®] to treat moderate-to-severe atopic dermatitis in adolescents (aged 12-17 years) met its primary and key secondary endpoints. The U.S. regulatory submission for patients aged 12-17 years is planned for third quarter 2018.
- **Mavacamten** (SAR439152/MYK461; partnership with MyoKardia), a myosin inhibitor, moved into phase 3 in obstructive hypertrophic cardiomyopathy (HCM). A phase 2 study in non-obstructive HCM also started.
- A trial evaluating **Cerdelga**[®] in pediatric type 1 Gaucher patients switching from ERT was initiated.
- A study evaluating **Praluent**[®] (collaboration with Regeneron) in children with heterozygous familial hypercholesterolemia (HeFH) was initiated.
- **Sotagliflozin** (partnership with Lexicon) moved into phase 3 in patients with worsening heart failure in diabetes.
- A phase 2/3 study evaluating **venglustat**, an oral glucosylceramide synthase (GCS) inhibitor, in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) is in the process of being initiated.
- A cardiovascular outcome study, AMPLITUDE-O, evaluating **efpeglenatide** was initiated.

Phase 2:

- **ALX-0171**, an anti RSV Nanobody[®], entered into Sanofi's portfolio through the acquisition of Ablynx.
- **SAR440340**, an anti-IL33 monoclonal antibody (partnership with Regeneron), is in the process of being initiated in a phase 2 study in chronic obstructive pulmonary disease (COPD).
- Phase 1/2a data on **BIVV001**, an extended factor VIII therapy, was presented at the World Federation of Hemophilia (WFH) and demonstrated a half-life of 37 hours.
- Decisions were taken to stop the development of **SAR566658**, a maytansin-loaded anti CA6 monoclonal antibody, in triple negative breast cancer and a recombinant subunit **vaccine against tuberculosis**.
- **ST-400**, a gene editing technology (collaboration between Sangamo and Ablynx), entered phase 2 in beta thalassemia.
- A phase 2 study evaluating **dupilumab** in grass immunotherapy was initiated.

2018 Second-quarter and first-half financial results⁽¹³⁾

Business Net Income⁽¹³⁾

In the second quarter of 2018, Sanofi generated **net sales** of €8,176 million, a decrease of 5.7% (up 0.1% at CER). First-half sales were €16,074 million, down 7.2% on a reported basis (down 0.1% at CER).

Second-quarter **other revenues** increased 13.0% (up 21.1% at CER) to €305 million, reflecting the VaxServe sales contribution of non-Sanofi products (€228 million, up 26.7% at CER) and the collaboration revenues from Swedish Orphan Biovitrum AB. First-half other revenues increased 2.7% (up 13.1% at CER) to €533 million of which €397 million were generated by VaxServe (up 20.1% at CER).

Second-quarter **Gross Profit** decreased 5.1% to €5,830 million (up 0.9% at CER). The gross margin ratio was 71.3% (71.3% at CER) versus 70.8% in the second quarter of 2017. The positive impact of business mix toward Specialty Care as well as the contribution from Bioverativ more than offset the negative impacts from U.S. Diabetes net price evolution and sevelamer generic competition. In the second quarter of 2018, the gross margin ratio of segments were 74.9% for Pharmaceuticals (up 0.1 percentage points), 67.4% for CHC (up 1.4 percentage points) and 55.1% for Vaccines (down 2.8 percentage points). First-half Gross Profit decreased 7.3% to €11,441 million (stable at CER). In the first half of 2018, the gross margin ratio decreased 0.1 percentage point to 71.2% (71.4% at CER) versus the first half of 2017. Sanofi expects its gross margin ratio to be between 70% and 71% at CER in 2018.

Research and Development (R&D) expenses increased 8.6% to €1,475 million in the second quarter of 2018. At CER, R&D expenses increased 13.1%, mainly reflecting the acquisitions of Bioverativ and Ablynx together with the investments in the immuno-oncology and diabetes programs. In 2018, second-quarter R&D expenses also included clinical materials for comparator studies purchased from a third party (which were recorded in R&D expenses); as part of the agreement, the expense (€58 million) was offset by income related to data shared with this same third party on a previously divested product candidate, which was recorded under the "other current operating income net of expenses" line. Excluding the impact of this transaction, second-quarter R&D expenses grew 8.6% at CER. First-half R&D expenses increased 3.3% to €2,755 million (up 8.9% at CER).

Second-quarter **selling general and administrative expenses (SG&A)** decreased 2.8% to €2,499 million. At CER, SG&A expenses were up 2.7% reflecting consolidation of Bioverativ and Ablynx and investments in immunology, which were partially offset by lower Diabetes expenses in the U.S. In the second quarter, the ratio of SG&A to sales increased 0.9 percentage points to 30.6% compared to the second quarter of 2017. First-half SG&A expenses decreased 4.8% to €4,809 million (up 1.8% at CER). In the first half of 2018, the ratio of SG&A to sales was 0.7 percentage points higher at 29.9% compared to the same period of 2017.

Second-quarter **other current operating income net of expenses** was €189 million versus €68 million in the second quarter of 2017 and included the share of profit to Regeneron of the monoclonal antibodies Alliance. In the second quarter of 2018, this line also included the Ablynx acquisition-related fees which were more than offset by €123 million of capital gains on disposals of some small products in Latin American and Europe, in line with our portfolio simplification efforts. This line also benefited from the aforementioned data share agreement. First-half other current operating income net of expenses was €158 million versus €102 million in the first half of 2017.

The **share of profits from associates** was €75 million in the second quarter versus €46 million for the same period of 2017 partly driven by the increased contribution of the share of profits in Regeneron. In the first half, the share of profits from associates was €149 million versus €70 million for the same period of 2017.

In the second quarter, **non-controlling interests** were -€28 million versus -€30 million in the second quarter of 2017. First-half non-controlling interests were -€58 million versus -€65 million for the same period of 2017.

Second-quarter **business operating income** decreased 8.9% to €2,092 million. At CER, business operating income decreased 1.0%. The ratio of business operating income to net sales decreased 0.9 percentage points to 25.6% versus the second quarter of 2017. Over the period, the business operating income ratio of segments were 37.5% for Pharmaceuticals (down 0.5 percentage points), 35.6% for CHC (up 8.7 percentage points) and 16.0% for Vaccines (down 9.7 percentage points). First-half business operating income was €4,126 million, down 12.8% (or down 3.8% at CER). In the first half of 2018 the ratio of business operating income to net sales decreased 1.6 percentage point to 25.7%.

Net financial expenses were -€107 million in the second quarter versus -€60 million in the same period of 2017. In the second quarter of 2018, net financial expenses included the cost associated with the Bioverativ and Ablynx acquisitions. First-half net financial expenses were -€105 million versus -€123 million in the first half of 2017.

⁽¹³⁾ See Appendix 3 for 2018 second-quarter consolidated income statement; see Appendix 10 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income.

The second-quarter **effective tax rate** was 22.0% compared to 24.5% in the second quarter of 2017, mainly reflecting the net positive impact of the U.S. tax reform and lower tax rates in different countries. First-half effective tax rate was 22.0% compared to 24.5% in the same period of 2017.

Second-quarter **business net income**⁽¹³⁾ decreased 7.9% to €1,558 million and increased 0.4% at CER. The ratio of business net income to net sales decreased 0.4 percentage points to 19.1% versus the second quarter of 2017. First-half 2018 business net income⁽¹³⁾ decreased 9.4% to €3,156 million and increased 0.4% at CER. The ratio of business net income to net sales decreased 0.5 percentage points to 19.6% versus the first half of 2017.

In the second quarter of 2018, **business earnings per share**⁽¹³⁾ (EPS) decreased 6.7% to €1.25 on a reported basis and increased 1.5% at CER. The average number of shares outstanding was 1,247.4 million versus 1,258.2 million in the second quarter of 2017.

In the first half of 2018, business earnings per share⁽¹³⁾ was €2.53, down 8.3% on a reported basis and up 1.4% at CER. The average number of shares outstanding was 1,247.8 million in the first half of 2018 versus 1,260.3 million in the first half of 2017.

Reconciliation of IFRS net income reported to business net income (see Appendix 4)

In the first half of 2018, the IFRS net income was €1,778 million. The main items excluded from the business net income were:

- An amortization charge of €999 million related to fair value remeasurement on intangible assets of acquired companies (primarily Aventis: €145 million, Genzyme: €385 million, Boehringer Ingelheim CHC business: €120 million, Bioverativ: €161 million) and to acquired intangible assets (licenses/products: €65 million). An amortization charge of €541 million related to fair value remeasurement on intangible assets of acquired companies (primarily Aventis: €72 million, Genzyme: €191 million, Boehringer Ingelheim CHC business: €60 million, Bioverativ: €124 million), and to acquired intangible assets (licenses/products: €32 million) was recorded in the second quarter. These items have no cash impact on the Company.
- An impairment of intangible assets of €101 million (of which €98 million in the second quarter) mainly related to Lemtrada[®] reflecting recent sales trends. This item has no cash impact on the Company.
- A charge of €99 million (of which €69 million in the second quarter) arising from the workdown of inventories of acquired companies (related to Bioverativ) remeasured at fair value due to the application of purchase accounting to acquisitions. This item has no cash impact on the Group.
- Restructuring costs and similar items of €607 million (of which €416 million in the second quarter) mainly related to accelerated depreciation of industrial assets and the U.S. and streamlining initiatives in Europe and Japan. In addition, restructuring costs includes the cost of transfer to Evotec of the early stage infectious diseases R&D portfolio and the Research unit for an amount of €253 million.
- A €475 million tax effect arising from the items listed above, mainly comprising €275 million of deferred taxes generated by amortization and impairments of intangible assets, and €183 million associated with restructuring costs and similar items. The second quarter tax effect was €290 million, including €153 million of deferred taxes on amortization charged against intangible assets and €131 million associated with restructuring costs and similar items (see Appendix 4).
- A €93 million tax effect (of which €27 million in the second quarter) arising mainly from the U.S. tax reform.
- An income of €74 million net of tax (of which €30 million in the second quarter) related to restructuring costs of associates and joint ventures, and expenses arising from the impact of acquisitions on associates and joint ventures.

(13) See Appendix 3 for 2018 second-quarter consolidated income statement; see Appendix 10 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income.

Capital Allocation

In the first half of 2018, net cash generated by operating activities was €1,854 million after capital expenditures of €689 million and an increase in working capital of €1,139 million. This net cash flow funded restructuring costs and similar items (€414 million) and share repurchases (€730 million). Over the period, the dividend paid by Sanofi was €3,773 million and acquisitions and partnerships net of disposals were €12,460 million (including €12,685 million related to Bioverativ and Ablynx). As a consequence, net debt increased from €5,229 million at December 31, 2017, to €21,278 million at June 30, 2018 (amount net of € 7,493 million cash and cash equivalents).

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions, and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Appendices

List of appendices

- Appendix 1: 2018 second-quarter and first-half net sales by GBU, franchise, geographic region and product
- Appendix 2: 2018 second-quarter and first-half Business net income statement
- Appendix 3: 2018 second-quarter and first-half Consolidated income statement
- Appendix 4: Reconciliation of IFRS net income reported to business net income
- Appendix 5: Change in net debt
- Appendix 6: Simplified consolidated balance sheet
- Appendix 7: Currency sensitivity
- Appendix 8: R&D pipeline
- Appendix 9: Expected R&D milestones
- Appendix 10: Definitions of non-GAAP financial indicators

Appendix 1: 2018 second-quarter net sales by GBU, franchise, geographic region and product

Q2 2018 (€ million)	Total GBUs	% CER	% reported	Europe	% CER	United States	% CER	Rest of the World	% CER	Emerging Markets	% CER	Total Franchises	% CER	% reported
Aubagio	391	0.2%	-5.6%	89	-21.1%	287	9.1%	15	-6.7%	13	36.4%	404	1.2%	-4.9%
Lemtrada	95	-16.1%	-19.5%	45	-2.1%	46	-20.6%	4	-62.5%	7	50.0%	102	-12.9%	-17.7%
Total Multiple Sclerosis	486	-3.4%	-8.6%	134	-15.5%	333	3.7%	19	-26.1%	20	41.2%	506	-2.0%	-7.8%
Cerezyme	120	-3.9%	-7.0%	68	-2.8%	42	-2.2%	10	-16.7%	61	15.4%	181	2.6%	-6.7%
Cerdelga	37	29.0%	19.4%	12	100.0%	23	13.0%	2	0.0%	1	-	38	32.3%	22.6%
Myozyme	179	9.4%	4.7%	95	9.2%	69	8.8%	15	12.5%	30	0.0%	209	7.8%	2.5%
Fabrazyme	168	7.2%	1.2%	45	9.8%	93	5.2%	30	10.3%	20	0.0%	188	6.3%	-1.1%
Aldurazyme	37	2.7%	0.0%	19	0.0%	11	9.1%	7	0.0%	15	-10.0%	52	-1.8%	-8.8%
Total Rare Disease	604	5.9%	1.0%	256	6.2%	263	3.7%	85	12.0%	139	7.1%	743	6.1%	-1.2%
Taxotere	9	-10.0%	-10.0%	1	0.0%	1	-	7	-11.1%	32	3.0%	41	0.0%	-4.7%
Jevtana	97	10.8%	4.3%	38	0.0%	43	14.6%	16	28.6%	6	0.0%	103	10.0%	3.0%
Eloxatine	9	0.0%	0.0%	0	-	0	-	9	0.0%	37	5.6%	46	4.4%	2.2%
Thymoglobulin	56	0.0%	-5.1%	10	0.0%	41	0.0%	5	0.0%	18	17.6%	74	3.9%	-2.6%
Mozobil	41	12.8%	5.1%	12	9.1%	24	8.3%	5	50.0%	3	100.0%	44	15.0%	10.0%
Zaltrap	21	40.0%	40.0%	13	0.0%	2	50.0%	6	-	3	33.3%	24	38.9%	33.3%
Total Oncology	266	0.0%	-5.3%	87	1.2%	126	-6.1%	53	17.0%	103	8.9%	369	2.4%	-3.4%
Dupixent	175	619.2%	573.1%	16	-	151	526.9%	8	-	1	-	176	623.1%	576.9%
Kevzara	20	2,100.0%	1,900.0%	3	-	15	1,600.0%	2	-	0	-	20	2,100.0%	1,900.0%
Total Immunology	195	674.1%	622.2%	19	-	166	566.7%	10	-	1	-	196	677.8%	625.9%
Alprolix	81	-	-	0	-	67	-	14	-	0	-	81	-	-
Eloctate	176	-	-	0	-	152	-	24	-	0	-	176	-	-
Total Rare blood disorders	257	-	-	0	-	219	-	38	-	0	-	257	-	-
Sanofi Genzyme (Specialty Care)	1,808	33.1%	25.7%	496	2.0%	1,107	50.9%	205	39.9%	263	10.3%	2,071	29.5%	21.1%
Lantus	647	-26.7%	-30.7%	174	-9.8%	403	-33.9%	70	-7.6%	244	1.1%	891	-20.6%	-25.5%
Toujeo	180	-0.5%	-5.3%	75	38.9%	86	-23.0%	19	42.9%	37	75.0%	217	7.9%	1.4%
Apidra	65	-2.9%	-5.8%	35	9.4%	19	-22.2%	11	10.0%	27	29.2%	92	5.4%	-1.1%
Amaryl	13	0.0%	-7.1%	4	-33.3%	1	-	8	12.5%	74	11.4%	87	9.5%	3.6%
Insuman	18	-14.3%	-14.3%	18	-10.0%	1	-	-1	-100.0%	5	-25.0%	23	-17.2%	-20.7%
Soliqua / Suliqua	16	240.0%	220.0%	2	-	14	220.0%	0	-	1	-	17	260.0%	240.0%
Total Diabetes	965	-19.2%	-23.4%	325	0.3%	525	-30.1%	115	1.7%	401	11.8%	1,366	-11.9%	-17.2%
Multaq	82	7.4%	1.2%	10	-9.1%	69	5.6%	3	-300.0%	1	0.0%	83	7.2%	0.0%
Praluent	60	51.2%	46.3%	22	100.0%	35	27.6%	3	200.0%	2	200.0%	62	54.8%	47.6%
Total Cardiovascular	142	22.1%	16.4%	32	45.5%	104	12.0%	6	-	3	66.7%	145	23.2%	16.0%
Diabetes & Cardiovascular	1,107	-15.6%	-19.8%	357	3.2%	629	-25.5%	121	5.8%	404	12.2%	1,511	-9.4%	-14.9%
Plavix	374	0.3%	-2.6%	38	-2.6%	0	-	58	-21.5%	278	7.1%	374	0.3%	-2.6%
Lovenox	377	-2.2%	-6.5%	227	-5.8%	8	-42.9%	21	-8.7%	121	10.6%	377	-2.2%	-6.5%
Renagel / Renvela	100	-57.3%	-59.7%	16	-15.8%	60	-68.9%	6	-30.0%	18	80.0%	100	-57.3%	-59.7%
Aprovel	171	-6.3%	-10.0%	27	-6.9%	3	-33.3%	21	-48.9%	120	12.6%	171	-6.3%	-10.0%
Allegra	28	-11.8%	-17.6%	3	-25.0%	0	-	25	-10.0%	0	-	28	-11.8%	-17.6%
Myslee / Ambien / Stilnox	55	-7.8%	-14.1%	9	-10.0%	12	-7.7%	20	-17.9%	14	15.4%	55	-7.8%	-14.1%
Synvisc / Synvisc One	92	-13.8%	-20.7%	7	-22.2%	66	-22.0%	3	0.0%	16	50.0%	92	-13.8%	-20.7%
Depakine	116	9.0%	4.5%	42	4.9%	0	-	4	0.0%	70	12.1%	116	9.0%	4.5%
Tritace	58	-1.6%	-6.5%	37	-5.1%	0	-	1	100.0%	20	0.0%	58	-1.6%	-6.5%
Other Rx Drugs	895	-2.7%	-7.0%	442	-1.8%	50	-7.3%	95	-16.5%	308	1.5%	895	-2.7%	-7.0%
Total Established Rx Products	2,266	-7.9%	-12.0%	848	-3.6%	199	-45.7%	254	-20.8%	965	7.8%	2,266	-7.9%	-12.0%
Generics	402	-1.6%	-8.6%	183	-3.2%	25	-15.6%	22	-19.4%	172	5.3%	402	-1.6%	-8.6%
Total Emerging Markets Specialty Care	263	10.3%	-3.3%							263	10.3%			
Total Emerging Markets Diabetes & Cardiovascular	404	12.2%	2.5%							404	12.2%			
General Medicines & Emerging Markets	3,335	-3.7%	-9.4%	1,031	-3.5%	224	-43.4%	276	-20.7%	1,804	8.9%			
Total Pharmaceuticals	6,250	1.9%	-3.8%	1,884	-0.9%	1,960	-0.4%	602	-1.4%	1,804	8.9%	6,250	1.9%	-3.8%
Allergy, Cough and Cold	239	2.0%	-5.2%	67	11.9%	68	-17.0%	24	7.7%	80	13.9%	239	2.0%	-5.2%
Pain	304	10.4%	1.7%	122	8.9%	41	-2.2%	30	3.2%	111	19.1%	304	10.4%	1.7%
Digestive	248	8.6%	1.6%	79	3.9%	47	2.0%	14	-6.3%	108	17.6%	248	8.6%	1.6%
Nutritional	166	0.6%	-6.7%	29	0.0%	9	-18.2%	65	4.5%	63	0.0%	166	0.6%	-6.7%
Consumer Healthcare	1,115	4.1%	-3.5%	324	6.6%	254	-5.8%	145	2.0%	392	10.1%	1,115	4.1%	-3.5%
Polio / Pertussis / Hib	354	-20.3%	-24.5%	68	-16.9%	65	-25.0%	40	10.3%	181	-24.3%	354	-20.3%	-24.5%
Adult Booster Vaccines	94	-14.8%	-18.3%	29	0.0%	56	-21.1%	6	0.0%	3	-20.0%	94	-14.8%	-18.3%
Meningitis/Pneumonia	116	-36.4%	-40.5%	0	-	90	-35.1%	3	-85.0%	23	-7.4%	116	-36.4%	-40.5%
Influenza Vaccines	98	7.1%	0.0%	0	-	0	-	19	133.3%	79	-5.6%	98	7.1%	0.0%
Travel And Other Endemic Vaccines	126	15.9%	11.5%	32	52.4%	40	0.0%	13	-7.1%	41	22.2%	126	15.9%	11.5%
Dengue	0	-100.0%	-100.0%	0	-	0	-	0	-	0	-100.0%	0	-100.0%	-100.0%
Vaccines	811	-15.7%	-20.2%	134	0.0%	265	-25.4%	83	0.0%	329	-15.5%	811	-15.7%	-20.2%
Total Company	8,176	0.1%	-5.7%	2,342	0.1%	2,479	-4.4%	830	-0.7%	2,525	5.2%	8,176	0.1%	-5.7%

2018 first-half net sales by GBU, franchise, geographic region and product

H1 2018 (€ million)	Total GBUs	% CER	% reported	Europe	% CER	United States	% CER	Rest of the World	% CER	Emerging Markets	% CER	Total Franchises	% CER	% reported
Aubagio	750	4.9%	-3.5%	184	-9.8%	541	11.0%	25	-7.1%	25	52.6%	775	6.0%	-2.6%
Lemtrada	195	-13.0%	-18.1%	92	1.1%	93	-19.2%	10	-43.8%	12	36.4%	207	-10.8%	-16.9%
Total Multiple Sclerosis	945	0.7%	-6.9%	276	-6.4%	634	5.2%	35	-20.5%	37	46.7%	982	2.0%	-6.0%
Cerezyme	236	-2.4%	-7.1%	134	-2.9%	83	1.1%	19	-13.0%	120	25.0%	356	6.2%	-3.8%
Cerdelga	73	27.4%	17.7%	22	100.0%	47	10.4%	4	33.3%	1	-	74	29.0%	19.4%
Myozyme	349	10.2%	4.5%	188	11.8%	133	9.6%	28	3.3%	56	5.0%	405	9.4%	2.8%
Fabrazyme	320	6.8%	-1.2%	87	7.4%	179	5.8%	54	9.3%	38	4.7%	358	6.5%	-2.5%
Aldurazyme	71	2.8%	-1.4%	38	0.0%	21	9.1%	12	0.0%	32	0.0%	103	1.8%	-6.4%
Total Rare Disease	1,170	4.9%	-1.4%	502	6.8%	509	3.5%	159	4.2%	268	13.3%	1,438	6.5%	-1.9%
Taxotere	17	-15.0%	-15.0%	2	0.0%	1	0.0%	14	-17.6%	67	2.9%	84	-1.1%	-6.7%
Jevtana	191	12.1%	4.9%	78	4.0%	84	16.0%	29	23.1%	11	-13.3%	202	10.2%	2.5%
Eloxatine	16	0.0%	-5.9%	1	-50.0%	0	-	15	6.7%	74	6.8%	90	5.6%	0.0%
Thymoglobulin	107	0.9%	-7.8%	19	-5.0%	78	2.4%	10	0.0%	37	25.0%	144	6.1%	-2.7%
Mozobil	77	7.8%	0.0%	24	9.1%	45	2.0%	8	50.0%	5	66.7%	82	10.0%	2.5%
Total Oncology	520	-5.3%	-11.6%	176	1.1%	248	-15.2%	96	20.0%	207	8.3%	727	-1.8%	-8.4%
Dupixent	282	1,088.5%	984.6%	26	-	246	950.0%	10	-	1	-	283	1,092.3%	988.5%
Kevzara	30	3,200.0%	2,900.0%	5	-	23	2,500.0%	2	-	0	-	30	3,200.0%	2,900.0%
Total Immunology	312	1,166.7%	1,055.6%	31	-	269	1,007.4%	12	-	1	-	313	1,170.4%	1,059.3%
Alprolix	102	-	-	0	-	83	-	19	-	0	-	102	-	-
Eloctate	219	-	-	0	-	187	-	32	-	0	-	219	-	-
Total Rare blood disorders	321	-	-	0	-	270	-	51	-	0	-	321	-	-
Sanofi Genzyme (Specialty Care)	3,268	24.8%	16.0%	985	4.9%	1,930	36.3%	353	27.7%	513	13.4%	3,781	23.1%	13.5%
Lantus	1,310	-25.6%	-31.3%	355	-9.4%	816	-32.4%	139	-7.9%	492	4.8%	1,802	-19.1%	-25.7%
Toujeo	349	1.6%	-4.6%	142	42.0%	171	-19.0%	36	31.0%	65	100.0%	414	10.7%	2.7%
Apidra	129	-5.6%	-9.8%	70	4.5%	40	-19.6%	19	0.0%	54	29.2%	183	3.1%	-4.2%
Amaryl	24	-16.1%	-22.6%	8	-27.3%	1	0.0%	15	-10.5%	146	10.6%	170	5.8%	-1.7%
Soliqua / Suliqua	25	211.1%	177.8%	2	-	23	188.9%	0	-	1	-	26	222.2%	188.9%
Total Diabetes	1,929	-18.6%	-24.4%	648	-0.3%	1,059	-28.3%	222	-1.6%	793	14.7%	2,722	-10.9%	-17.8%
Multaq	159	-1.7%	-10.2%	21	-4.5%	135	-1.9%	3	100.0%	3	0.0%	162	-1.7%	-10.5%
Praluent	107	52.7%	44.6%	41	115.8%	61	26.4%	5	150.0%	4	150.0%	111	55.3%	46.1%
Total Cardiovascular	266	14.3%	6.0%	62	51.2%	196	5.3%	8	133.3%	7	50.0%	273	15.2%	6.2%
Diabetes & Cardiovascular	2,195	-15.6%	-21.6%	710	2.7%	1,255	-24.6%	230	0.0%	800	15.0%	2,995	-9.0%	-16.1%
Plavix	761	4.6%	-0.4%	76	-2.6%	0	-	110	-25.3%	575	14.6%	761	4.6%	-0.4%
Lovenox	768	-1.5%	-6.0%	471	-5.4%	20	-24.1%	41	-4.3%	236	9.9%	768	-1.5%	-6.0%
Renagel / Renvela	201	-55.7%	-59.3%	32	-13.5%	121	-67.5%	15	-10.5%	33	59.1%	201	-55.7%	-59.3%
Aprovel	343	-4.7%	-10.2%	55	-8.3%	5	-16.7%	41	-50.5%	242	15.1%	343	-4.7%	-10.2%
Allegra	80	-14.7%	-21.6%	5	-16.7%	0	-	75	-14.6%	0	-	80	-14.7%	-21.6%
Myslee / Ambien / Stinolx	116	-8.0%	-15.3%	20	0.0%	22	-14.3%	42	-17.5%	32	9.4%	116	-8.0%	-15.3%
Synvisc / Synvisc One	160	-14.6%	-22.3%	13	-23.5%	111	-22.2%	7	-12.5%	29	43.5%	160	-14.6%	-22.3%
Depakine	230	7.6%	2.7%	84	2.4%	0	-	7	-12.5%	139	12.0%	230	7.6%	2.7%
Tritace	115	-2.4%	-7.3%	73	-6.4%	0	-	2	50.0%	40	2.3%	115	-2.4%	-7.3%
Other Rx Drugs	1,812	-3.1%	-8.5%	890	-2.6%	100	-2.7%	190	-12.2%	632	-0.8%	1,812	-3.1%	-8.5%
Total Established Rx Products	4,586	-7.1%	-12.3%	1,719	-3.9%	379	-44.1%	530	-20.0%	1,958	8.7%	4,586	-7.1%	-12.3%
Generics	837	-0.3%	-7.6%	367	-4.7%	48	-21.7%	71	21.9%	351	4.1%	837	-0.3%	-7.6%
Total Emerging Markets Specialty Care	513	13.4%	-0.4%							513	13.4%			
Total Emerging Markets Diabetes & Cardiovascular	800	15.0%	4.0%							800	15.0%			
General Medicines & Emerging Markets	6,736	-2.6%	-9.2%	2,086	-4.1%	427	-42.2%	601	-16.6%	3,622	10.2%			
Total Pharmaceuticals	12,199	0.5%	-6.4%	3,781	-0.6%	3,612	-5.4%	1,184	-3.5%	3,622	10.2%	12,199	0.5%	-6.4%
Allergy, Cough and Cold	580	-4.2%	-12.0%	167	1.2%	173	-19.4%	78	4.9%	162	7.6%	580	-4.2%	-12.0%
Pain	628	9.6%	0.6%	254	1.2%	78	-2.2%	57	5.2%	239	24.9%	628	9.6%	0.6%
Digestive	496	11.7%	3.8%	163	1.2%	95	12.8%	27	7.1%	211	20.5%	496	11.7%	3.8%
Nutritional	330	2.0%	-6.3%	62	1.6%	18	-9.1%	123	2.3%	127	3.6%	330	2.0%	-6.3%
Consumer Healthcare	2,353	3.0%	-5.3%	706	0.0%	541	-5.3%	305	2.5%	801	12.3%	2,353	3.0%	-5.3%
Polio / Pertussis / Hib	734	-12.8%	-18.5%	139	0.7%	176	-10.0%	81	4.8%	338	-21.4%	734	-12.8%	-18.5%
Adult Booster Vaccines	186	2.1%	-4.1%	66	43.5%	97	-11.6%	13	7.7%	10	-21.4%	186	2.1%	-4.1%
Meningitis/Pneumonia	205	-22.1%	-29.3%	0	-100.0%	157	-21.0%	7	-63.6%	41	-6.3%	205	-22.1%	-29.3%
Influenza Vaccines	127	0.7%	-6.6%	1	-	4	66.7%	24	36.8%	98	-7.9%	127	0.7%	-6.6%
Travel And Other Endemic Vaccines	228	9.6%	4.1%	59	37.2%	62	-5.6%	28	7.1%	79	9.1%	228	9.6%	4.1%
Vaccines	1,522	-9.3%	-15.4%	271	16.2%	524	-12.6%	158	0.6%	569	-16.7%	1,522	-9.3%	-15.4%
Total Company	16,074	-0.1%	-7.2%	4,758	0.3%	4,677	-6.3%	1,647	-2.1%	4,992	6.8%	16,074	-0.1%	-7.2%

Appendix 2: Business net income statement

Second quarter 2018	Pharmaceuticals			Consumer Healthcare			Vaccines			Others ⁽²⁾			Total Group		
€ million	Q2 2018	Q2 2017 ⁽¹⁾	Change	Q2 2018	Q2 2017 ⁽¹⁾	Change	Q2 2018	Q2 2017 ⁽¹⁾	Change	Q2 2018	Q2 2017 ⁽¹⁾	Change	Q2 2018	Q2 2017 ⁽¹⁾	Change
Net sales	6,250	6,499	(3.8%)	1,115	1,156	(3.5%)	811	1,016	(20.2%)	-	-	-	8,176	8,671	(5.7%)
Other revenues	76	72	5.6%	-	-	-	229	197	16.2%	-	1	(100.0%)	305	270	13.0%
Cost of sales	(1,643)	(1,709)	(3.9%)	(364)	(393)	(7.4%)	(593)	(625)	(5.1%)	(51)	(71)	(28.2%)	(2,651)	(2,798)	(5.3%)
As % of net sales	(26.3%)	(26.3%)		(32.6%)	(34.0%)		(73.1%)	(61.5%)					(32.4%)	(32.3%)	
Gross profit	4,683	4,862	(3.7%)	751	763	(1.6%)	447	588	(24.0%)	(51)	(70)	(27.1%)	5,830	6,143	(5.1%)
As % of net sales	74.9%	74.8%		67.4%	66.0%		55.1%	57.9%					71.3%	70.8%	
Research & Development expenses	(1,135)	(999)	13.6%	(30)	(30)	-	(142)	(137)	3.6%	(168)	(192)	(12.5%)	(1,475)	(1,358)	8.6%
As % of net sales	(18.2%)	(15.4%)		(2.7%)	(2.6%)		(17.5%)	(13.5%)					(18.0%)	(15.7%)	
Selling and general expenses	(1,394)	(1,422)	(2.0%)	(399)	(444)	(10.1%)	(173)	(193)	(10.4%)	(533)	(513)	3.9%	(2,499)	(2,572)	(2.8%)
As % of net sales	(22.3%)	(21.9%)		(35.8%)	(38.4%)		(21.3%)	(19.0%)					(30.6%)	(29.7%)	
Other current operating income/ expenses	139	8		77	25		(2)	4		(25)	31		189	68	
Share of profit/loss of associates* and joint-ventures	75	47		-	-		-	(1)		-	-		75	46	
Net income attributable to non-controlling interests	(26)	(27)		(2)	(3)		-	-		-	-		(28)	(30)	
Business operating income	2,342	2,469	(5.1%)	397	311	27.7%	130	261	(50.2%)	(777)	(744)	4.4%	2,092	2,297	(8.9%)
As % of net sales	37.5%	38.0%		35.6%	26.9%		16.0%	25.7%					25.6%	26.5%	
Financial income and expenses													(107)	(60)	
Income tax expenses													(427)	(545)	
Tax rate**													22.0%	24.5%	
Business net income													1,558	1,692	(7.9%)
As % of net sales													19.1%	19.5%	
Business earnings / share (in euros) ***													1.25	1.34	(6.7%)

* Net of tax.

** Determined on the basis of Business income before tax, associates and non-controlling interests.

*** Based on an average number of shares outstanding of 1,247.4 million in the second quarter of 2018 and 1,258.2 million in the second quarter of 2017.

(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018

(2) Other includes the cost of global support functions (Medical Affairs, External Affairs, Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc...).

First Half 2018	Pharmaceuticals			Consumer Healthcare			Vaccines			Others ⁽²⁾			Total Group		
€ million	H1 2018	H1 2017 ⁽¹⁾	Change	H1 2018	H1 2017 ⁽¹⁾	Change	H1 2018	H1 2017 ⁽¹⁾	Change	H1 2018	H1 2017 ⁽¹⁾	Change	H1 2018	H1 2017 ⁽¹⁾	Change
Net sales	12,199	13,038	(6.4%)	2,353	2,486	(5.3%)	1,522	1,800	(15.4%)	-	-	-	16,074	17,324	(7.2%)
Other revenues	134	148	(9.5%)	-	-	-	399	370	7.8%	-	1	(100.0%)	533	519	2.7%
Cost of sales	(3,230)	(3,419)	(5.5%)	(763)	(818)	(6.7%)	(1,068)	(1,123)	(4.9%)	(105)	(135)	(22.2%)	(5,166)	(5,495)	(6.0%)
As % of net sales	(26.5%)	(26.2%)		(32.4%)	(32.9%)		(70.2%)	(62.4%)					(32.1%)	(31.7%)	
Gross profit	9,103	9,767	(6.8%)	1,590	1,668	(4.7%)	853	1,047	(18.5%)	(105)	(134)	(21.6%)	11,441	12,348	(7.3%)
As % of net sales	74.6%	74.9%		67.6%	67.1%		56.0%	58.2%					71.2%	71.3%	
Research & Development expenses	(2,113)	(1,999)	5.7%	(58)	(52)	11.5%	(268)	(260)	3.1%	(316)	(356)	(11.2%)	(2,755)	(2,667)	3.3%
As % of net sales	(17.3%)	(15.3%)		(2.5%)	(2.1%)		(17.6%)	(14.4%)					(17.1%)	(15.4%)	
Selling and general expenses	(2,648)	(2,807)	(5.7%)	(788)	(880)	(10.5%)	(326)	(363)	(10.2%)	(1,047)	(1,004)	4.3%	(4,809)	(5,054)	(4.8%)
As % of net sales	(21.7%)	(21.5%)		(33.5%)	(35.4%)		(21.4%)	(20.2%)					(29.9%)	(29.2%)	
Other current operating income/ expenses	132	41		82	57		-	1		(56)	3		158	102	
Share of profit/loss of associates* and joint-ventures	150	71		-	-		(1)	(1)		-	-		149	70	
Net income attributable to non-controlling interests	(52)	(54)		(6)	(11)		-	-		-	-		(58)	(65)	
Business operating income	4,572	5,019	(8.9%)	820	782	4.9%	258	424	(39.2%)	(1,524)	(1,491)	2.2%	4,126	4,734	(12.6%)
As % of net sales	37.5%	38.5%		34.8%	31.5%		17.0%	23.6%					25.7%	27.3%	
Financial income and expenses													(105)	(123)	
Income tax expenses													(865)	(1,129)	
Tax rate**													22.0%	24.5%	
Business net income													3,156	3,482	(9.4%)
As % of net sales													19.6%	20.1%	
Business earnings / share (in euros) ***													2.53	2.76	(8.3%)

* Net of tax.

** Determined on the basis of Business income before tax, associates and non-controlling interests.

*** Based on an average number of shares outstanding of 1,247.8 million in the first half of 2018 and 1,260.3 million in the first half of 2017.

(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018

(2) Other includes the cost of global support functions (Medical Affairs, External Affairs, Finance, Human Resources, Information Solution & Technologies, Sanofi Business Services, etc...).

Appendix 3: Consolidated income statements

€ million	Q2 2018	Q2 2017 ⁽¹⁾	H1 2018	H1 2017 ⁽¹⁾
Net sales	8,176	8,671	16,074	17,324
Other revenues	305	270	533	519
Cost of sales	(2,720)	(2,886)	(5,265)	(5,671)
Gross profit	5,761	6,055	11,342	12,172
Research and development expenses	(1,475)	(1,358)	(2,755)	(2,667)
Selling and general expenses	(2,507)	(2,572)	(4,819)	(5,054)
Other operating income	298	113	323	173
Other operating expenses	(109)	(45)	(165)	(71)
Amortization of intangible assets	(541)	(487)	(999)	(990)
Impairment of intangible assets	(98)	(12)	(101)	(12)
Fair value remeasurement of contingent consideration liabilities	66	(64)	10	(100)
Restructuring costs and similar items	(416)	(245)	(607)	(364)
Other gains and losses and litigation	(18)	(7)	(67)	(7)
Operating income	961	1,378	2,162	3,080
Financial expenses	(107)	(107)	(202)	(218)
Financial income	-	47	97	95
Income before tax and associates and joint ventures	854	1,318	2,057	2,957
Income tax expense	(110)	(276)	(297)	(612)
Share of profit/loss of associates and joint ventures	45	27	75	27
Net income excluding the held for exchange Animal Health business	789	1,069	1,835	2,372
Net income from the held for exchange Animal Health business	1	(6)	-	4,421
Net income	790	1,063	1,835	6,793
Net income attributable to non-controlling interests	28	30	57	64
Net income attributable to equity holders of Sanofi	762	1,033	1,778	6,729
Average number of shares outstanding (million)	1,247.4	1,258.2	1,247.8	1,260.3
Earnings per share (in euros) excluding the held for exchange Animal Health business	0.61	0.83	1.42	1.83
IFRS earnings per share (in euros)	0.61	0.82	1.42	5.34

(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018

(2) In 2017 net gain resulting from the divestment of the Animal Health business presented separately in accordance with IFRS5, Non current assets held-for-sale and discontinued operations.

Appendix 4: Reconciliation of business net income to consolidated net income attributable to equity holders of Sanofi

€ million	Q2 2018	Q2 2017 ⁽¹⁾	Change
Net income attributable to equity holders of Sanofi	762	1,033	(26.2%)
Amortization of intangible assets ⁽²⁾	541	487	
Impairment of intangible assets	98	12	
Fair value remeasurement of contingent consideration	(66)	64	
Expenses arising from the impact of acquisitions on inventories	69	88	
Other expenses related to business combinations	8	-	
Restructuring costs and similar items	416	245	
Other gains and losses, and litigation ⁽³⁾	18	7	
Tax effect of items listed above:	(290)	(380)	
<i>Amortization & impairment of intangible assets</i>	<i>(153)</i>	<i>(167)</i>	
<i>Fair value remeasurement of contingent consideration</i>	<i>17</i>	<i>(25)</i>	
<i>Expenses arising from the impact of acquisitions on inventories</i>	<i>(17)</i>	<i>(28)</i>	
<i>Other expenses related to business combinations</i>	<i>1</i>	<i>-</i>	
<i>Restructuring costs and similar items</i>	<i>(131)</i>	<i>(83)</i>	
<i>Other tax effects</i>	<i>(7)</i>	<i>(77)</i>	
Other tax items ⁽⁴⁾	(27)	111	
Share of items listed above attributable to non-controlling interests	-	-	
Restructuring costs of associates and joint-ventures, and expenses arising from the impact of acquisitions on associates and joint-ventures	30	19	
Animal Health items ⁽⁵⁾	(1)	6	
Business net income	1,558	1,692	(7.9%)
IFRS earnings per share⁽⁶⁾ (in euros)	0.61	0.82	

(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018.

(2) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations: €509 million in the second quarter of 2018 and €453 million in the second quarter of 2017

(3) In 2018, separation costs for the European Generics business divestiture.

(4) In 2018, adjustments made to our preliminary analysis of the direct and indirect impacts of US tax reform. In 2017, relates to French 3% tax on dividends.

(5) In 2017, net gain resulting from divestment of the Animal Health business presented separately in accordance with IFRS 5, Non current assets held-for-sale and discontinued operations.

(6) Based on an average number of shares outstanding of 1,247.4 million in the second quarter of 2018 and 1,258.2 million in the second quarter of 2017.

€ million	H1 2018	H1 2017 ⁽¹⁾	Change
Net income attributable to equity holders of Sanofi	1,778	6,729	(73.6%)
Amortization of intangible assets ⁽²⁾	999	990	
Impairment of intangible assets	101	12	
Fair value remeasurement of contingent Consideration	(10)	100	
Expenses arising from the impact of acquisitions on inventories	99	176	
Other expenses related to business combinations	10	-	
Restructuring costs and similar items	607	364	
Other gains and losses, and litigation ⁽³⁾	67	7	
Tax effect of items listed above:	(475)	(628)	
<i>Amortization & impairment of intangible assets</i>	(275)	(349)	
<i>Fair value remeasurement of contingent consideration</i>	11	(31)	
<i>Expenses arising from the impact of acquisitions on inventories</i>	(23)	(56)	
<i>Other expenses related to business combinations on inventories</i>	-	-	
<i>Restructuring costs and similar items</i>	(183)	(126)	
<i>Other tax effects</i>	(5)	(66)	
Other tax items ⁽⁴⁾	(93)	111	
Share of items listed above attributable to non-controlling interests	(1)	(1)	
Restructuring costs of associates and joint-ventures, and expenses arising from the impact of acquisitions on associates and joint-ventures	74	43	
Animal Health items ⁽⁵⁾	-	(4,421)	
Business net income	3,156	3,482	(9.4%)
IFRS earnings per share⁽⁶⁾ (in euros)	1.42	5.34	

(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018

(2) Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combination: €934 million in the first-half of 2018 and €919 million in the first-half of 2017

(3) In 2018, separation costs for the European Generics business divestiture.

(4) In 2018, adjustments made to our preliminary analysis of the direct and indirect impacts of US tax reform. In 2017, relates to French 3% tax on dividends.

(5) In 2017, net gain resulting from the divestment of the Animal Health business presented separately in accordance with IFRS 5, Non current assets held-for-sale and discontinued operations.

(6) Based on an average number of shares outstanding of 1,247.8 million in the first-half of 2018 and 1,260.3 million in the first-half of 2017.

Appendix 5: Change in net debt

€ million	H1 2018	H1 2017 ⁽¹⁾
Business net income	3,156	3,482
Depreciation amortization and impairment of property, plant and equipment and software	591	604
Gains and losses on disposals of non-current assets, net of tax	(216)	(79)
Other non-cash items	151	167
Operating cash flow before changes in working capital ⁽²⁾	3,682	4,174
Changes in working capital ⁽²⁾	(1,139)	(1,187)
Acquisitions of property, plant and equipment and software	(689)	(688)
Free cash flow ⁽²⁾	1,854	2,299
Acquisitions of intangibles, excluding software	(77)	(285)
Acquisitions of investments, in consolidated undertakings including assumed debt	(12,872)	(274)
Restructuring costs and similar items paid	(414)	(438)
Proceeds from disposals of property, plant and equipment, intangibles, and other non-current assets, net of tax	489	313
Issuance of Sanofi shares	19	99
Dividends paid to shareholders of Sanofi	(3,773)	(3,710)
Acquisition of treasury shares	(730)	(1,698)
Transactions with non-controlling interests including dividends	(18)	(48)
Foreign exchange impact	(210)	290
Net cash-flow from the swap between BI – CHC and Sanofi Animal Health business	5	4,349
Other items	(322)	(154)
Change in net debt	(16,049)	743

(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018

(2) Excluding restructuring costs and similar items

Appendix 6: Simplified consolidated balance sheet

ASSETS € million		Jun 30, 2018	Dec 31, 2017 ⁽¹⁾	LIABILITIES & EQUITY € million		Jun 30, 2018	Dec 31, 2017 ⁽¹⁾
				Equity attributable to equity-holders of Sanofi		56,197	58,070
				Equity attributable to non-controlling interests		164	169
				Total equity		56,361	58,239
				Long-term debt		22,788	14,326
Property, plant and equipment	9,470	9,579		Non-current liabilities related to business combinations and to non-controlling interests		1,018	1,026
Intangible assets (including goodwill)	67,264	53,344		Provisions and other non-current liabilities		8,949	9,154
Non-current financial assets, investments in associates, and deferred tax assets	10,575	10,502		Deferred tax liabilities		3,784	1,605
Non-current assets	87,309	73,425		Non-current liabilities		36,539	26,111
				Accounts payable and other current liabilities		13,004	13,845
Inventories, accounts receivable and other current assets	16,443	16,039		Current liabilities related to business combinations and to non-controlling interests		450	343
Cash and cash equivalents	7,493	10,315		Short-term debt and current portion of long-term debt		6,153	1,275
Current assets	23,936	26,354		Current liabilities		19,607	15,463
Assets held for sale or exchange	1,533	34		Liabilities related to assets held for sale or exchange		271	-
Total ASSETS	112,778	99,813		Total LIABILITIES & EQUITY		112,778	99,813

(1) Includes the effects of first-time application of IFRS 15 on revenue recognition, effective January 1, 2018

Appendix 7 : currency sensitivity

2018 Business EPS currency sensitivity

Currency	Variation	Business EPS Sensitivity
U.S. Dollar	+0.05 USD/EUR	-EUR 0.10
Japanese Yen	+5 JPY/EUR	-EUR 0.01
Chinese Yuan	+0.2 CNY/EUR	-EUR 0.02
Brazilian Real	+0.4 BRL/EUR	-EUR 0.02
Russian Ruble	+10 RUB/EUR	-EUR 0.03

Currency exposure on Q2 2018 sales

Currency	Q2 2018
US \$	31.1%
Euro €	25.2%
Chinese Yuan	7.3%
Japanese Yen	5.1%
Brazilian Real	2.7%
British Pound	2.1%
Russian Ruble	2.0%
Australian \$	1.7%
Canadian \$	1.6%
Mexican Peso	1.4%
Others	19.8%

Currency average rates

	Q2 2017	Q2 2018	Change
€/\$	1.10	1.19	+8.4%
€/Yen	122.15	130.15	+6.6%
€/Yuan	7.54	7.60	+0.9%
€/Real	3.54	4.30	+21.5%
€/Ruble	62.87	74.02	+17.7%

Appendix 8: R&D Pipeline

O : Opt-in rights products for which rights have not been exercised yet
R : Registrational Study (other than Phase 3)

Immuno-inflammation
Oncology
Rare Diseases

Rare Blood Disorders
MS & Neuro
Diabetes

Cardiovascular & metabolism
Vaccines

New Molecular Entities^(*)

Phase 1 (Total : 16)		Phase 2 (Total : 13)		Phase 3 (Total : 8)	Registration (Total : 3)
SAR439794 TLR4 agonist Peanut Allergy	SAR228810 Anti-protofibrillar AB mAb Alzheimer's Disease	SAR440340^(**) Anti-IL33 mAb Asthma	ST400⁽⁸⁾ ZFN Gene Editing Technology Beta thalassemia	isatuximab Anti-CD38 mAb 3L Relapsing Refractory MM (ICARIA)	cemiplimab^(**) PD-1 inhibitor mAb Advanced CSCC (U.S./EU)
SAR408701 Maytansin-loaded anti-CEACAM5 mAb Solid Tumors	UshStat[®] Myosin 7A gene therapy Usher Syndrome 1B	SAR156597 IL4/IL13 bispecific mAb Systemic Scleroderma	SAR422459 ABCA4 gene therapy Stargardt Disease	avalglucosidase alfa Neo GAA Pompe Disease	Zynquista^{TM(**)} Oral SGLT-1&2 inhibitor Type 1 Diabetes (U.S./EU)
SAR439459 anti-TGFβ mAb Advanced Solid Tumors	SAR442168⁽⁴⁾ BTK inhibitor Multiple Sclerosis	GZ389988 TRKA antagonist Osteoarthritis	SAR425899 GLP-1/GCG dual agonist Obesity/Overweight in T2D	venglustat Oral GCS inhibitor ADPKD ⁽¹⁰⁾	CabliviTM Bivalent anti-vWF Nanobody acquired Thrombotic Thrombocytopenic Purpura (EU)
REGN3767⁽¹⁾ Anti-LAG-3 mAb Advanced Cancers	SAR438335 GLP-1/GIP dual agonist Type 2 Diabetes	Combination ferroquine / OZ439^(**) Antimalarial	SAR407899 rho kinase Microvascular Angina	fitusiran siRNA targeting Anti-Thrombin Hemophilia A and B	
REGN4659⁽¹⁾ Anti-CTLA-4 mAb Cancer	SAR440181^{(5)(**)} Myosin activation Dilated Cardiomyopathy	ALX0171 Anti RSV Nanobody Respiratory Syncytial Virus	HIV Viral vector prime & rgp120 boost vaccine	sutimlimab⁽¹¹⁾ Anti Complement C1s mAb Cold Agglutinin Disease	
REGN4018⁽¹⁾ Anti-MUC16-CD3 bispecific mAb Ovarian Cancer	SAR247799 S1P1 agonist Cardiovascular indication	R olipudase alfa rhASM Acid Sphingomyelinase Deficiency ⁽⁶⁾	SP0232⁽⁹⁾ mAb^(**) Respiratory syncytial virus Monoclonal Antibody	SAR341402 Rapid acting insulin Type 1/2 Diabetes	
SAR439859 SERD Metastatic Breast Cancer	Herpes Simplex Virus Type 2 HSV-2 vaccine	O SAR339375⁽⁷⁾ miRNA-21 Alport Syndrome		efpeglenatide^(**) Long-acting GLP-1 agonist Type 2 Diabetes	
BIVV001⁽²⁾ rFVIII Fc – vWF – XTEN ⁽³⁾ Hemophilia A	Respiratory syncytial virus Infants Vaccines			mavacamten^{(12)(**)} Myosin inhibitor - Obstructive Hypertrophic Cardiomyopathy	

(1) Regeneron product for which Sanofi has opt-in rights
(2) Sanofi Product for which Sobi has opt-in rights
(3) Recombinant Coagulation Factor VIII Fc – von Willebrand Factor – XTEN Fusion protein
(4) Also known as PRN2246
(5) Also known as MYK491
(6) Also known as Niemann Pick type B
(7) Regulus product for which Sanofi has opt-in rights

(8) Developed in collaboration with Sangamo
(9) Also known as MEDI8897
(10) Autosomal Dominant Polycystic Kidney Disease
(11) Also known as BIVV009
(12) Also known as SAR439152 and MYK461
(*) Data related to all studies published on clinicaltrials.gov
(**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products

Additional Indications^(*)

Phase 1 (Total : 6)	Phase 2 (Total : 16)		Phase 3 (Total : 20)		Registration (Total : 5)
SAR439459 + cemiplimab^(**) Anti-TGFb mAb + PD-1 inhibitor mAb Advanced Solid Tumors	dupilumab^(**) Anti-IL4Rα mAb Eosinophilic Esophagitis	venglustat Oral GCS inhibitor Gaucher Type 3	dupilumab^(**) Anti-IL4Rα mAb Asthma 6 - 11 years old	cemiplimab^(**) PD-1 inhibitor mAb + platinum based chemotherapy 1L NSCLC	dupilumab^(**) Anti-IL4Rα mAb Asthma 12y+ (U.S./EU)
cemiplimab^(**) + REGN3767⁽¹⁾ PD-1 inhibitor mAb + Anti-LAG-3 mAb Advanced Cancers	dupilumab^(**) Anti-IL4Rα mAb Grass Immunotherapy	venglustat Oral GCS inhibitor Fabry Disease	dupilumab^(**) Anti-IL4Rα mAb Nasal Polyposis	Aubagio[®] teriflunomide Relapsing Multiple Sclerosis – Pediatric	Praluent^{®(**)} alirocumab CV events reduction (U.S. ⁽⁴⁾ /EU)
cemiplimab^(**) + REGN4659⁽¹⁾ PD-1 inhibitor mAb + Anti-CTLA-4 mAb NSCLC	R sarilumab^(**) Anti-IL6R mAb Polyarticular Juvenile Idiopathic Arthritis	venglustat Oral GCS inhibitor Gaucher related Parkinson's Disease	Dupixent^{®(**)} dupilumab Atopic Dermatitis 12 – 17 years old	Lemtrada[®] alemtuzumab Relapsing Remitting Multiple Sclerosis - Pediatric	VaxiGrip[®] QIV IM Quadrivalent inactivated Influenza vaccine 6 - 35 months
cemiplimab^(**) + REGN4018⁽¹⁾ PD-1 inhibitor mAb + Anti-MUC16-CD3 bispecific mAb - Ovarian Cancer	sarilumab^(**) Anti-IL6R mAb Systemic Juvenile Arthritis	mavacamten^{(3)(**)} Myosin inhibitor Non -Obstructive Hypertrophic Cardiomyopathy	Dupixent^{®(**)} dupilumab Atopic Dermatitis 6 – 11 years old	Zynquista^{TM(**)} Oral SGLT-1&2 inhibitor Worsening Heart Failure in Diabetes	PR5i DTP-HepB-Polio-Hib Pediatric hexavalent vaccines (U.S.)
SAR439859 SERD + Palbociclib Metastatic Breast Cancer	R SAR440340^(**) Anti-IL33 mAb COPD	Rabies VRVg Purified vero rabies vaccine	Dupixent^{®(**)} dupilumab Atopic Dermatitis 6 months - 5 years old	Zynquista^{TM(**)} Oral SGLT-1&2 inhibitor Type 2 Diabetes	Fluzone[®] 0,5 mL QIV Quadrivalent inactivated Influenza vaccine 6 months+
sutimlimab⁽²⁾ Anti Complement C1s mAb Immune Thrombocytopenia	cemiplimab^(**) PD-1 inhibitor mAb Advanced Basal Cell Carcinoma	Adacel+ Tdap booster	cemiplimab^(**) PD-1 inhibitor mAb 1L NSCLC	Cerdelga[®] eliglustat Gaucher Type 1, switch from ERT - Pediatric	
	isatuximab + cemiplimab^(**) Anti-CD38 mAb + PD-1 inhibitor mAb Relapsing Refractory MM	Shan 6 DTP-HepB-Polio-Hib Pediatric hexavalent vaccine	cemiplimab^(**) PD-1 inhibitor mAb 2L Cervical Cancer	Praluent^{®(**)} alirocumab LDL-C reduction - Pediatric	
	isatuximab + cemiplimab^(**) Anti-CD38 mAb + PD-1 inhibitor mAb Advanced Malignancies		cemiplimab^(**) PD-1 inhibitor mAb + ipilimumab 1L NSCLC	Fluzone[®] QIV HD Quadrivalent inactivated Influenza vaccine - High dose	
	cemiplimab^(**) PD-1 inhibitor mAb 2L NSCLC		isatuximab Anti-CD38 mAb 1L Newly Diagnosed MM (IMROZ)	Men Quad TT Advanced generation meningococcal ACYW conjugate vaccine	
			isatuximab Anti-CD38 mAb 1-3L Relapsing Refractory MM (IKEMA)	Pediatric pentavalent vaccine DTP-Polio-Hib Japan	

(1) Regeneron product for which Sanofi has opt-in rights

(2) Also known as BIVV009

(3) Also known as SAR439152 and MYK461

(4) U.S. filing pending acceptance by FDA

(*) Data related to all studies published on clinicaltrials.gov

(**) Partnered and/or in collaboration - Sanofi may have limited or shared rights on some of these products

Expected Submission Timeline⁽¹⁾

	New Molecular Entities		Additional Indications	
2018	isatuximab anti-CD38 mAb 3L RRMM (ICARIA)		Dupixent^{®(**)} dupilumab AD 12 – 17 years old	
2019	SAR341402 Rapid acting insulin Type 1/2 Diabetes – EU ⁽²⁾		Dupixent^{®(**)} dupilumab AD 6 - 11 years old	dupilumab^(**) Anti-IL4Ra mAb Nasal Polyposis Adult
			cemiplimab^(**) PD-1 inhibitor mAb Advanced BCC	Zynquista^{TM(**)} Oral SGLT-1&2 inhibitor Type 2 Diabetes – EU ⁽³⁾
			Fluzone[®] QIV HD Quadrivalent inactivated Influenza vaccine - High dose	Men Quad TT Adv. generation meningococcal U.S.: 2y+ & EU: Toddlers+
			Pentacel[®] vIPV DTaP-IPV/Hib	
2020	olipudase alfa rhASM ASD ⁽⁴⁾	fitusiran siRNA inhibitor Hemophilia A/B	sarilumab^(**) Anti-IL6R mAb Polyarticular Juvenile Idiopathic Arthritis – U.S./EU	isatuximab Anti-CD38 mAb 1-3L RRMM (IKEMA)
	avalglucosidase alfa NeoGAA Pompe Disease		cemiplimab^(**) PD-1 inhibitor mAb 2L Cervical Cancer	cemiplimab^(**) PD-1 inhibitor mAb 1L NSCLC
	sutimlimab⁽⁵⁾ Anti Complement C1s mAb Cold Agglutinin Disease		Aubagio[®] teriflunomide Relapsing MS – Pediatric	Shan 6 DTP-HepB-Polio-Hib Pediatric hexavalent vaccine

	New Molecular Entities		Additional Indications	
2021	efpeglenatide^(**) Long acting GLP1-R agonist Type 2 Diabetes		isatuximab Anti-CD38 mAb 1L Newly Diagnosed MM (IMROZ)	Zynquista^{TM(**)} Oral SGLT 1/2 inhibitor Worsening Heart Failure in Diabetes
	venglustat Oral GCS inhibitor ADPKD ⁽⁶⁾		cemiplimab^(**) PD-1 inhibitor mAb + platinum based chemotherapy 1L NSCLC	Pediatric pentavalent vaccine DTP-Polio-Hib (Japan)
				Adacel+ Tdap booster
2022 and beyond	GZ389988 TRKA antagonist Osteoarthritis	SAR156597 IL4/IL13 bispecific mAb Systemic Scleroderma	Dupixent^{®(**)} dupilumab AD 6 months - 5 years old	sarilumab^(**) Anti-IL6R mAb Systemic Juvenile Arthritis
	SAR440340^(**) Anti-IL33 mAb Asthma	ALX0171 Anti RSV Nanobody Respiratory Syncytial Virus	dupilumab^(**) Anti-IL4Ra mAb Eosinophilic Esophagitis	dupilumab^(**) Anti-IL4Ra mAb Asthma 6 - 11 years old
	Combination ferroquine / OZ439^(**) Antimalarial	SAR228810 Anti-protofibrillar AB mAb Alzheimer's Disease	SAR440340^(**) Anti-IL33 mAb COPD	venglustat Oral GCS inhibitor Gaucher Type 3
	SAR422459 ABCA4 gene therapy Stargardt Disease	SAR407899 rho kinase Microvascular Angina	venglustat Oral GCS inhibitor Fabry Disease	Cerdelga[®] eliglustat Gaucher Type 1, switch from ERT Pediatric – EU
	SAR425899 GLP-1/GCG dual agonist Obesity/Overweight in T2D	SP0232 mAbs^{(7)(**)} Respiratory syncytial virus	Praluent^{®(**)} alirocumab LDL-C reduction – Pediatric	Rabies VRVg Purified vero rabies vaccine
	HIV Viral vector prime & rgp120 boost vaccine		venglustat Oral GCS inhibitor GrPD ⁽⁸⁾	

(1) Excluding Phase 1 - Data related to all studies published on clinicaltrials.gov

(2) Submission strategy for the U.S. under evaluation

(3) Submission for the U.S. expected in 2020

(4) Acid Sphingomyelinase Deficiency

(5) Also known as BIVV009; Currently operating as separate entities. Reported dates are based on prior Bioverativ disclosure of study completion date

(6) Autosomal Dominant Polycystic Kidney Disease

(7) Also known as MEDI8897

(8) Gaucher Related Parkinson's Disease

(**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products

Pipeline Movements Since Q1 2018

	Additions		Removals
Registration	Cablivi™ Nanobody Bivalent anti-vWF Purpura thrombotique thrombocytopenique acquis (EU)		
	Praluent®(1) alirocumab - Réduction des attaques cardiovasculaires (U.S. ⁽¹⁾ /EU)		
Phase 3	mavacamten^{(2)(**)} Myosin inhibitor - Obstructive Hypertrophic Cardiomyopathy	Zynquista™(1) Oral SGLT-1&2 inhibitor Worsening Heart Failure in Diabetes	
	Praluent®(1) alirocumab LDL-C reduction- Pediatric	cemiplimab⁽¹⁾ PD-1 inhibitor mAb + ipilimumab 1L NSCLC	
	Cerdelga® eliglustat Gaucher disease Type 1, switch from ERT Pediatric	cemiplimab⁽¹⁾ PD-1 inhibitor mAb + platinum based chemotherapy 1L NSCLC	
	venglustat Oral GCS inhibitor ADPKD ⁽³⁾		
Phase 2	dupilumab⁽¹⁾ Anti-IL4Rα mAb Grass Immunotherapy	ST400⁽⁴⁾ ZFN Gene Editing Technology Beta thalassemia	SAR566658 Maytansin-loaded anti-CA6 mAb Triple Negative Breast Cancer
	SAR440340⁽¹⁾ Anti-IL33 mAb COPD	mavacamten^{(2)(**)} Myosin inhibitor Non -Obstructive Hypertrophic Cardiomyopathy	Tuberculosis Recombinant subunit vaccine
	ALX0171 Anti RSV Nanobody Respiratory Syncytial Virus	cemiplimab⁽¹⁾ PD-1 inhibitor mAb 2L NSCLC	
Phase 1	<input type="checkbox"/> REGN4018⁽⁵⁾ Anti-MUC16-CD3 bispecific mAb Cancer	<input type="checkbox"/> cemiplimab⁽¹⁾ + REGN4659⁽⁵⁾ PD-1 inhibitor mAb + Anti-CTLA-4 mAb NSCLC	
	<input type="checkbox"/> REGN4018⁽⁵⁾ Anti-MUC16-CD3 bispecific mAb Ovarian Cancer	<input type="checkbox"/> cemiplimab⁽¹⁾ + REGN4018⁽⁵⁾ PD-1 inhibitor mAb + Anti-CTLA-4 mAb Ovarian Cancer	

(**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products

(5) Regeneron product for which Sanofi has opt-in rights

- (1) U.S. filing pending acceptance by FDA
 (2) Also known as SAR439152 and MYK46
 (3) Autosomal Dominant Polycystic Kidney Disease
 (4) Developed in collaboration with Sangamo

Appendix 9: Expected R&D milestones

Products	Expected milestones	Timing
Praluent [®]	U.S. sBLA filing to include ODYSSEY OUTCOMES results ⁽¹⁾	Q3 2018
isatuximab	Start of Phase 3 in 1 st line Multiple Myeloma in SCT eligible patients (GMMG)	Q3 2018
Cablivi [™] (caplacizumab)	U.S. FDA filing in acquired Thrombotic Thrombocytopenic Purpura	Q3 2018
venglustat	Start of Pivotal study in Autosomal Dominant Polycystic Kidney Disease	Q3 2018
MenQuadTT	Phase 3 results for prevention of Meningococcal Meningitis	Q3 2018
Dupixent [®]	U.S. FDA filing in Atopic Dermatitis in Adolescent patients	Q3 2018
Fluzone [®] QIV HD	Phase 3 results for prevention of Influenza	Q4 2018
cemiplimab	U.S. regulatory decision in locally advanced CSCC	Q4 2018
dupilumab	U.S. regulatory decision in Asthma in Adult/Adolescent patients	Q4 2018
dupilumab	Start of Phase 2b/3 trial in Chronic Obstructive Pulmonary Disease	Q4 2018
isatuximab	Phase 3 results in Multiple Myeloma in combination with PomDex (ICARIA)	Q4 2018
dupilumab	Phase 3 read-out in Nasal Polyps	Q4 2018
efpeglenatide	Start of Phase 3 in Type 2 Diabetes as add-on to metformin vs dulaglutide	Q4 2018
efpeglenatide	Start of Phase 3 in Type 2 Diabetes as add-on to basal insulins	Q4 2018
dupilumab	Start of Phase 3 trial in Eosinophilic Esophagitis	Q4 2018
alemtuzumab	Start of Phase 3 in Primary Progressive Multiple Sclerosis	H2 2018
Zynquista [™] (sotagliflozin)	EU CHMP decision expected in Type 1 Diabetes	Q1 2019
cemiplimab	EU CHMP decision expected in Advanced Cutaneous Squamous Cell Carcinoma	Q1 2019

(1) Praluent[®] ODYSSEY OUTCOMES results submitted to the FDA in Q2 2018; submission is pending acceptance by FDA

Appendix 10: Definitions of non-GAAP financial indicators

Company

“Company” corresponds to Sanofi and its subsidiaries

Company sales at constant exchange rates (CER)

When we refer to changes in our net sales “at constant exchange rates” (CER), this means that we exclude the effect of changes in exchange rates.

We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period.

Reconciliation of net sales to Company sales at constant exchange rates for the second quarter and first half 2018

€ million	Q2 2018	H1 2018
Net sales	8,176	16,074
Effect of exchange rates	(508)	(1,227)
Company sales at constant exchange rates	8,684	17,301

Business net income

Sanofi publishes a key non-GAAP indicator.

Business net income is defined as net income attributable to equity holders of Sanofi excluding:

- amortization of intangible assets,
- impairment of intangible assets,
- fair value remeasurement of contingent consideration related to business combinations or to disposals,
- other impacts associated with acquisitions (including impacts of acquisitions on associates and joint ventures),
- restructuring costs and similar items⁽¹⁾,
- other gains and losses (including gains and losses on disposals of non-current assets⁽¹⁾),
- costs or provisions associated with litigation⁽¹⁾,
- tax effects related to the items listed above as well as effects of major tax disputes,
- net income attributable to non-controlling interests related to the items listed above,

(1) Reported in the line items **Restructuring costs and similar items** and **Gains and losses on disposals, and litigation**, which are defined in Note B.20. to our consolidated financial statements.